{"id":10212,"date":"2026-07-10T09:06:51","date_gmt":"2026-07-10T14:06:51","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10212"},"modified":"2026-07-10T09:14:18","modified_gmt":"2026-07-10T14:14:18","slug":"nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/","title":{"rendered":"Nanoscope Therapeutics presentar\u00e1 sus novedades en la Reuni\u00f3n Cient\u00edfica Anual de la Sociedad Estadounidense de Especialistas en Retina de 2026."},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"10212\" class=\"elementor elementor-10212\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6d5ad04f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6d5ad04f\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5bf9bdef\" data-id=\"5bf9bdef\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e3a8c93 elementor-widget elementor-widget-text-editor\" data-id=\"e3a8c93\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><i>El Dr. Jordi Mon\u00e9s presentar\u00e1 el primer ensayo cl\u00ednico aleatorizado y controlado de fase 2 de terapia optogen\u00e9tica en la degeneraci\u00f3n macular.<\/i><\/li><li><i>Benjamin Bakall, MD, PhD, presentar\u00e1 datos de seguimiento duraderos de 3 a\u00f1os del estudio REMAIN del ensayo RESTORE de fase 2b\/3 de MCO-010 en retinosis pigmentaria.<\/i><\/li><\/ul><p><strong><span class=\"legendSpanClass\">MONTREAL<\/span>,\u00a0<span class=\"legendSpanClass\">10 de julio de 2026<\/span><\/strong>\u00a0 \u2014 Nanoscope Therapeutics, Inc., una empresa de biotecnolog\u00eda comprometida con el desarrollo y la comercializaci\u00f3n de terapias novedosas e independientes de la enfermedad para pacientes con p\u00e9rdida de fotorreceptores y discapacidad visual debido a la degeneraci\u00f3n retiniana, anunci\u00f3 hoy que los datos cl\u00ednicos de sus programas de terapia optogen\u00e9tica se presentar\u00e1n en el <b>Sociedad Americana de Especialistas en Retina (ASRS) 44<sup>th<\/sup>\u00a0Reuni\u00f3n Cient\u00edfica Anual, que tendr\u00e1 lugar del 15 al 18 de julio de 2026 en el Palais des Congr\u00e8s de Montr\u00e9al en Montreal, Canad\u00e1.<\/b><\/p><p>Las presentaciones destacar\u00e1n la entrada de Nanoscope en el campo de la degeneraci\u00f3n macular asociada a la edad (DMAE) con un nuevo ensayo cl\u00ednico de terapia optogen\u00e9tica en la atrofia geogr\u00e1fica (AG) que eval\u00faa la mejora de la visi\u00f3n, y datos de durabilidad a largo plazo para MCO-010 en la retinosis pigmentaria (RP).<\/p><p><b>Detalles de la presentaci\u00f3n:<\/b><\/p><p><b>T\u00edtulo:<\/b>\u00a0<i>Mejora de la visi\u00f3n con la terapia optogen\u00e9tica Sonpiretigene Isteparvovec en la degeneraci\u00f3n macular: primer ensayo cl\u00ednico aleatorizado y controlado directo a fase 2.<\/i><\/p><p><b>Presentador:<\/b>\u00a0Jordi Mon\u00e9s, Doctor en Medicina, Doctor en Filosof\u00eda<br \/><b>Sesi\u00f3n:<\/b>\u00a0DMAE \u2013 Simposio 1 sobre enfermedades no neovasculares: \u201cM\u00e1s all\u00e1 de la atrofia: Restaurando la visi\u00f3n y redefiniendo la atenci\u00f3n en la atrofia geogr\u00e1fica\u201d<br \/><b>Fecha y hora:<\/b>\u00a0Jueves, 16 de julio | 13:46<\/p><p><b>T\u00edtulo:<\/b>\u00a0<i>Mejora duradera de la visi\u00f3n con la terapia optogen\u00e9tica MCO-010: datos de seguimiento REMAIN a 3 a\u00f1os del ensayo RESTORE de fase 2b\/3 para la retinosis pigmentaria.<br \/><\/i><b>Presentador:<\/b>\u00a0Benjamin Bakall, Doctor en Medicina, Doctor en Filosof\u00eda<br \/><b>Formato:<\/b>\u00a0Presentaci\u00f3n bajo demanda<\/p><p><b>Acerca de la plataforma MCO<br \/><\/b>La opsina multicaracter\u00edstica (MCO) es una plataforma terap\u00e9utica intrav\u00edtrea de una sola aplicaci\u00f3n, ambulatoria y aplicable a cualquier enfermedad, dise\u00f1ada para restaurar la visi\u00f3n en pacientes con degeneraci\u00f3n de fotorreceptores, incluyendo retinosis pigmentaria (RP), enfermedad de Stargardt (ES) y atrofia geogr\u00e1fica (AG). Al activar las c\u00e9lulas bipolares de la retina, altamente densas, para que sean sensibles a la luz, la MCO aprovecha el circuito visual restante tras la muerte de los fotorreceptores. El tratamiento con MCO no requiere pruebas gen\u00e9ticas, cirug\u00eda invasiva ni dosis repetidas, lo que permite una amplia aplicabilidad en pacientes dentro de los flujos de trabajo habituales en las consultas de retina.<\/p><p><b>Acerca de Nanoscope Therapeutics<br \/><\/b>Nanoscope Therapeutics est\u00e1 desarrollando una terapia optogen\u00e9tica restauradora de la visi\u00f3n, independiente de la enfermedad, para millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos del ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo RESTORE Fase 2b\/3 para la retinosis pigmentaria (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>), se ha presentado una BLA a la FDA. Si se aprueba, MCO-010 tiene el potencial de convertirse en el tratamiento est\u00e1ndar para pacientes con RP, administrado como una inyecci\u00f3n \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de MCO-010 en SD (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>) y planea iniciar una\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/\" target=\"_blank\" rel=\"nofollow noopener\">Ensayo de registro de fase 3<\/a>\u00a0en 2026. MCO-010 ha recibido las designaciones de v\u00eda r\u00e1pida y medicamento hu\u00e9rfano de la FDA para RP y SD, junto con la designaci\u00f3n RMAT para SD, y las designaciones de medicamento hu\u00e9rfano de la EMA para cubrir distrofias dominantes de bastones y conos no sindr\u00f3micas y sindr\u00f3micas, as\u00ed como distrofias maculares. MCO-010 ha recibido las designaciones de Sakigake y medicamento hu\u00e9rfano para distrofias retinianas hereditarias (IRD) en Jap\u00f3n y una designaci\u00f3n de medicamento hu\u00e9rfano para IRD en Arabia Saudita. Se espera que un programa de fase 2 para MCO en GA comience en 2026. Otros programas listos para IND incluyen la amaurosis cong\u00e9nita de Leber (LCA).<\/p><p>Contacto:<br class=\"dnr\" \/>Nanoscope Therapeutics, Inc<br class=\"dnr\" \/>(817) 857-1186<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Jordi Mon\u00e9s, MD, PhD, to Introduce First Direct-to-Phase 2 Randomized, Controlled Trial of Optogenetic Therapy in Macular Degeneration Benjamin Bakall, MD, PhD, to Present Durable 3-Year REMAIN Follow-Up Data from the RESTORE Phase 2b\/3 Trial of MCO-010 in Retinitis Pigmentosa MONTREAL,\u00a0July 10, 2026\u00a0 &#8212; Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10213,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10212","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-10T14:06:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-10T14:14:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting\",\"datePublished\":\"2026-07-10T14:06:51+00:00\",\"dateModified\":\"2026-07-10T14:14:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\\\/\"},\"wordCount\":497,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_ASRS26.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\\\/\",\"name\":\"Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_ASRS26.jpg\",\"datePublished\":\"2026-07-10T14:06:51+00:00\",\"dateModified\":\"2026-07-10T14:14:18+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_ASRS26.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_ASRS26.jpg\",\"width\":2000,\"height\":2000},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-07-10T14:06:51+00:00","article_modified_time":"2026-07-10T14:14:18+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Wilson PJ","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting","datePublished":"2026-07-10T14:06:51+00:00","dateModified":"2026-07-10T14:14:18+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/"},"wordCount":497,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_ASRS26.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/","url":"https:\/\/nanostherapeutics.com\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/","name":"Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_ASRS26.jpg","datePublished":"2026-07-10T14:06:51+00:00","dateModified":"2026-07-10T14:14:18+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_ASRS26.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_ASRS26.jpg","width":2000,"height":2000},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/07\/10\/nanoscope-therapeutics-to-present-at-2026-american-society-of-retina-specialists-annual-scientific-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"Wilson P.J."}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=10212"}],"version-history":[{"count":7,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10212\/revisions"}],"predecessor-version":[{"id":10220,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10212\/revisions\/10220"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/10213"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=10212"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=10212"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=10212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}